Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer

Study summary

The investigators will evaluate the feasibility of implementing a low-intensity, patient-centered activity regimen (PCAR) that prioritizes education and communication over a 12-week period in advanced stage lung cancer patients. The primary outcomes will include number of patients increasing their overall step count over the study period and adherence to step count recommendations. Secondary outcomes will include quality of life (QoL), dyspnea, and depression scores before and after the intervention as well as a patient feedback questionnaire (to guide further interventions). The goals are to increase overall step count and obtain adherence of \>50% of participants. The investigators will also assess whether the physical activity regimen influences markers of inflammation and glucose control and novel markers of cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPrescribed Activity

The study team can explain what participation involves.

Who it may be forLung Neoplasm Malignant

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 15, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Yale University

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: Yale University
Interventions being studied: Behavioral: Prescribed Activity

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Study topics

Survivorship and quality of life→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pathologic evidence of advanced non-small cell stage lung cancer (NSCLC)
Approval of the treating clinician
Adult patients (age \>21 years) willing to wear a FitBit® device (FitBit, Inc., San Francisco, CA)
Access to a smartphone, agree to receive twice/daily text messages for 12 weeks (including any costs), and willingness to download the FitBit application to their smartphone.
Low activity level as judged by a brief physical activity questionnaire (i.e., \<150 minutes/week of moderate-intensity exercise, \<75 minutes/week of vigorous aerobic exercise, or an equivalent combination).

Reasons someone may not be able to joinExclusion criteria

Memory impairment (as judged by the treating clinician)
Communication impairment (as judged by the treating clinician)
Treating clinician's request not to alter physical activity
Physical inability to safely walk (as judged by the treating clinician)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Yale UniversityNew Haven, Connecticut

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 15, 2024. Always confirm current availability with the study team.

View original record ↗